Browse Almada, Anthony

1-55 out of 55 article(s)

Title	Type	Date	Words
Proprietary puncture: part III: proprietary compositions and 'blends'enjoy partial insulation ... but what if regulatory agencies and consumers could dereplicate them?		Dec 1, 2011	653
Proprietary puncture: part II: proprietary compositions and "blends" enjoy partial insulation ... but what if regulatory agencies and consumers could dereplicate them?		Nov 1, 2011	719
Proprietary puncture: part I: proprietary compositions and 'blends' enjoy partial insulation ... but what if regulatory agencies and consumers could dereplicate them?		Oct 1, 2011	634
A real class act(ion): what if 'consumer' class action suits achieved more than just consumer redress?		Sep 1, 2011	704
The Ethos of 'Ethics'.		Jul 1, 2011	672
Eviscerating 'evidence': a gut feeling: what if there was a way to objectively evaluate the consumer-relevant efficacy of a probiotic, in a physician's office?	Case overview	Jun 1, 2011	684
Abstract artistic license: what if errant labeling statements and descriptions led to public excoriation and regulatory seizure?		May 1, 2011	657
Ear-relevant: what if there were no regulations (and thus no enforcement) regarding nutrition product claims?		Jan 1, 2011	662
What's My Evidence I: What if nutraceutical marketers had their claims verified in a public forum by a savvy expert who also was aligned with federal regulators?		Dec 1, 2010	670
The value chain gang: quantum leapers: what if the norm was for active nutritional ingredient manufacturers to launch and grow their own consumer brands?		Nov 1, 2010	675
Consumer confidence confluence: what if a wholly independent entity dutifully served consumers by evaluating consumer products in a compelling and inspiring manner?		Oct 1, 2010	693
Ipsilateral IP: patent pending impotence: what are salient elements related to the creation and exploitation of knowledge assets aspiring to become a patentable invention?		Sep 1, 2010	692
A few bad actors: remiss reporting: does the glass-paneled architecture that houses all of the conflicted stakeholders allow insiders to count the real size and inadequacy of the rogue-acting troupe?		Jul 1, 2010	726
Energy beverage bashing & coffee cognizance: nutraceuticals multiverse a quirky account of what could/may be happening in parallel universes/dimensions.		Jun 1, 2010	793
Dynamics of kinetics.		May 1, 2010	784
Evidence rules vs. evidentiary rules: a quirky account of what could/may be happening in parallel universes/dimensions.		Apr 1, 2010	736
Editor v. advertiser: an expected victory: what if there was a clone of this world of nutraceuticals, an identical twin, of the nutraceuticals industry, that existed in a different time/space dimension, where practices, choices and decisions could be played out differently than they are on this planet? What could a nutraceuticals business exec learn and extract, to infuse their brand with a proprietary, competitive edge?		Mar 1, 2010	614
Back to school II: probiotic 'friendly fire': nutraceuticals multiverse: a quirky account of what could/may be happening in parallel universes/dimensions.		Jan 1, 2010	700
Nutraceuticals multiverse: a quirky account of what could/may be happening in parallel universes/dimensions.		Dec 1, 2009	698
Research and destroy: nutraceuticals Multiverse a quirky account of what could/may be happening in parallel universes/dimensions.		Oct 1, 2009	651
Undercover uncoverings I: GMP or GIMP? Nutraceuticals Multiverse: a quirky account of what could/may be happening in parallel universes/dimensions.		Sep 1, 2009	681
Confliction affliction.		Jul 1, 2009	695
Weighty disclosure: what if there was a clone of this world of nutraceuticals, an identical twin of the nutraceuticals industry, that existed in a different time/space dimension, where practices, choices and decisions could be played out differently than they are on this planet? What could a nutraceuticals business exec learn and extract, to infuse their brand with a proprietary, competitive edge?		May 1, 2009	555
Speaker shock.	Interview	Apr 1, 2009	675
Functional fools & enriched evanescence.		Mar 1, 2009	680
Pinprick or hemorrhage: nutraceuticals Multiverse a quirky account of what could/may be happening in parallel universes/dimensions.		Jan 1, 2009	574
Hetero sapiens: the crack in the crystal ball: what happens when you compare clinical trial results in different populations?		Dec 1, 2008	879
I'm a formulator': a fictional account of a TV show featuring product formulators with no true formulation experience.		Oct 1, 2008	784
Post-Patent pendency inclemency: Trailblazing with blindfolds: Examining strategies your company can employ when your patents are pending.		Jul 1, 2008	834
The illusion of veracity; Tales from the trail of the comeback kid.		May 1, 2008	800
Prize pHight: who says the natural products industry should decry drugs with OTC status? The opportunity for exploiting underappreciated weaknesses in the digestive health category, au naturel, is explosive.		Mar 1, 2008	808
Friday night fights: head to head comparisons reveal the superiority of dietary ingredients, but this path is least traveled.		Oct 1, 2007	731
The velvet rope I: the case of the severed joint; Examining the long, windy, expensive road in patent litigation.		Jul 1, 2007	729
Endurance in the time of evanescence: what are some indicators of a brand or ingredient that can endure regulatory scrutiny, sustain robust revenues, and be embraced by the masses for more than a decade?		May 1, 2007	801
Spirited guide to industry: the tug of war continues between faith, reality and dietary supplements.		Mar 1, 2007	756
Exclusivity agreement: exclude the bad & exalt the good; As the dearth of blockbuster bioactives continues, the drive to inflate the small into the superior and the new into allowed proceeds unabated.		Dec 1, 2006	814
Weighting for Godot: the wait for a weight loss bioactive marvel demands patience, risk tolerance, and investment, while many industrial players prefer to eschew patience and mitigate risk by resigning to commodity platforms that are often unsustainable.		Oct 1, 2006	790
Trendspotting: the glycemic gulf; In the exodus from low carb, what promises and consumer realities await the adoption of low glycemic?	Clinical report	Jul 1, 2006	861
Tomb of the unknown science: Part II; What would happen if a whistle was placed in the mouth of a seasoned industry scientist--and he blew into it?	Column	May 1, 2006	1239
Tomb of the Unknown Science: Part I; What would happen if a whistle was placed in the mouth of a seasoned industry scientist?		Mar 1, 2006	880
Flags of convenience or banners of obfuscation? Are consumers being told the whole story and are marketers being made aware of all the facts?		Dec 1, 2005	944
Disjointed & disinformed: can the missteps of the past and the presumed positive outcome of the biggest joint health study create incremental business and resurrect consumer confidence?		Oct 1, 2005	854
The China Syndrome: the economic impact of China on nutraceutical bioactives is to be reckoned with, but "quality" may no longer be a lightning rod.		Jul 1, 2005	718
Monocular vision & the lone gunwoman; Nature meets science: one molecule, one target mantra or ... systems nutrition?		May 1, 2005	832
Ethnic exuberance: irrational? How long until genotypic and metabolic individuality, and the bright line circumscribed by ethnic gene pools, eclipse 'one-product-fits-all' marketing and positioning?		Mar 1, 2005	908
Waiting for Dr. Godot: the wait for a "Carl Sagan" for evidence-based nutraceuticals has morphed into a relentless ultramarathon.		Dec 1, 2004	881
Old dogs, new tricks, bigger hoops: the allure of creating an economic advantage with ostensibly "generic" ingredients is gaining momentum and is fueling industrial and academic investment.		Oct 1, 2004	676
Weapons of (muscle) mass production: sports nutrition market landscape 2004; Which element is driving the future development of the sports nutrition market--evangelism, evidence or evolution by regulation?		Oct 1, 2004	3376
A tale of two cities: as the debate rages amidst a national frenzy over no/low carb, one ostensibly unheard evidence-based answer has already been provided.		Jul 1, 2004	890
The raconteur & the realist: for whom do the bells toll? Taking a look at the state of flux as influenced by FDA, competitive tactics and a palpable tolerance of anecdotes and testimonials.		May 1, 2004	825
The emperor has new clothes: science for sale and "science" for seals.		Mar 1, 2004	1043
Immune to ignorance I. De facto "experts": when white coat knowledge ventures into nutritional science, does Doctor know best?	Column	Oct 1, 2003	885
A different spin on quality: when searching for the heir apparent to the throne held by the 'Queen of Quality,' should we look for a chemist or a biologist?		Oct 1, 2003	2274
Innovation Telescope: Galileo revisited; A discussion with Galileo's Dr. Guy Miller reveals where the company has been and where it is headed.	Interview	Jul 1, 2003	1361
Two 'gals' from innovation: whatever happened to Galileo Laboratories and GalaGen?		Mar 1, 2003	2123